Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrance in HR+ metastatic breast cancer after PI3K inhibitors
NCT02384239Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2015
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by University of California, San Francisco. Started Oct 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02384239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384239.